Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s00432-018-2740-3.

Title:
Role of ferroptosis in hepatocellular carcinoma | Journal of Cancer Research and Clinical Oncology
Description:
Purpose Hepatocellular carcinoma (HCC) is a complicated disease with low survival rate due to frequent recurrence and the lack of efficient therapies. For advanced HCC, sorafenib, as the only approved first-line drug for HCC, improves the survival to some extent, but depressingly with severe adverse effects and emerging resistance conditions, which cause a poor prognosis. Ferroptosis is a new recognized way of non-apoptosis-regulated cell death, characterized by the iron-dependent accumulation of lipid hydroperoxides, showing a tremendous promising in the therapy of cancer, especially in HCC. To provide ideas for the diagnosis and treatment of HCC, we summarized the role of ferroptosis in HCC. Methods The relevant literature from PubMed is reviewed in this article. Results Interestingly enough, investigators have found sorafenib can induce ferroptosis in HCC. Moreover, recent researches reported increasing pathways and mechanisms related to ferroptosis in HCC such as TP53 and Rb, and strategies to improve sorafenib resistance by targeting ferroptosis. In addition, other drugs were reported to induce ferroptosis in HCC such as erastin and showed good efficacy in vivo and in vitro. Conclusion In this review, we summarize pathways and mechanisms of ferroptosis in HCC and other digestive system neoplasms such as gastric cancer, pancreatic cancer and colorectal cancer and point out the trends of ferroptosis in HCC.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {šŸ“š}

  • Education
  • Health & Fitness
  • Science

Content Management System {šŸ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {šŸ“ˆ}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {šŸ’ø}

We find it hard to spot revenue streams.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {šŸ”}

article, pubmed, google, scholar, cas, cancer, ferroptosis, carcinoma, cell, hepatocellular, central, cells, sorafenib, death, hcc, res, induces, human, research, zheng, pancreatic, chen, role, treatment, access, protein, tumor, kang, foundation, privacy, cookies, content, journal, publish, tongsen, resistance, lipid, nrf, glutathione, wang, sun, biophys, oncol, tang, china, harbin, data, search, clinical, oncology,

Topics {āœ’ļø}

er stress-induced p53-independent long-chain acyl-coenzyme month download article/chapter p62-keap1-nrf2 pathway protects low-density lipoprotein iron-dependent cell death p53-mediated molecular control pd-l1/dnmt1 axis promote liver tumorigenesis raf/mek/erk pathway glutathione-dependent enzymes represent state-province key laboratories apoptosis-regulated cell death human hepatocellular carcinoma ferroptotic cell death hepatocellular carcinoma cells tongsen zheng advanced hepatocellular carcinoma full article pdf iron storage function corosolic acid induces mitochondrial lipid peroxidation iron-dependent accumulation iron-dependent form inhibits ferroptosis induced inhibits tumor angiogenesis natural science foundation nrf2 transcription factor privacy choices/manage cookies gene expression alterations nonapoptotic cell death tumour suppressor status related subjects cysteinyl-trna synthetase apoptotic cell death anti-tumor action author information authors pancreatic cancer cells cisd1 inhibits ferroptosis synthetase family hepatocellular carcinoma nrf2 enhances resistance keap1-nrf2 pathway breast cancer cells article nie sorafenib induces ferroptosis targeting antitumor compounds yang ws piperlongumine rapidly induces global cancer statistics

Schema {šŸ—ŗļø}

WebPage:
      mainEntity:
         headline:Role of ferroptosis in hepatocellular carcinoma
         description:Hepatocellular carcinoma (HCC) is a complicated disease with low survival rate due to frequent recurrence and the lack of efficient therapies. For advanced HCC, sorafenib, as the only approved first-line drug for HCC, improves the survival to some extent, but depressingly with severe adverse effects and emerging resistance conditions, which cause a poor prognosis. Ferroptosis is a new recognized way of non-apoptosis-regulated cell death, characterized by the iron-dependent accumulation of lipid hydroperoxides, showing a tremendous promising in the therapy of cancer, especially in HCC. To provide ideas for the diagnosis and treatment of HCC, we summarized the role of ferroptosis in HCC. The relevant literature from PubMed is reviewed in this article. Interestingly enough, investigators have found sorafenib can induce ferroptosis in HCC. Moreover, recent researches reported increasing pathways and mechanisms related to ferroptosis in HCC such as TP53 and Rb, and strategies to improve sorafenib resistance by targeting ferroptosis. In addition, other drugs were reported to induce ferroptosis in HCC such as erastin and showed good efficacy in vivo and in vitro. In this review, we summarize pathways and mechanisms of ferroptosis in HCC and other digestive system neoplasms such as gastric cancer, pancreatic cancer and colorectal cancer and point out the trends of ferroptosis in HCC.
         datePublished:2018-08-22T00:00:00Z
         dateModified:2018-08-22T00:00:00Z
         pageStart:2329
         pageEnd:2337
         sameAs:https://doi.org/10.1007/s00432-018-2740-3
         keywords:
            Hepatocellular carcinoma
            Ferroptosis
            Sorafenib
            Lipid metabolism
            Iron
            Therapy
            Oncology
            Cancer Research
            Internal Medicine
            Hematology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-018-2740-3/MediaObjects/432_2018_2740_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-018-2740-3/MediaObjects/432_2018_2740_Fig2_HTML.gif
         isPartOf:
            name:Journal of Cancer Research and Clinical Oncology
            issn:
               1432-1335
               0171-5216
            volumeNumber:144
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Jianhua Nie
               affiliation:
                     name:Cancer Hospital of Harbin Medical University
                     address:
                        name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Binlin Lin
               affiliation:
                     name:Cancer Hospital of Harbin Medical University
                     address:
                        name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Meng Zhou
               affiliation:
                     name:Cancer Hospital of Harbin Medical University
                     address:
                        name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Li Wu
               affiliation:
                     name:Cancer Hospital of Harbin Medical University
                     address:
                        name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Tongsen Zheng
               url:http://orcid.org/0000-0002-7539-3924
               affiliation:
                     name:Cancer Hospital of Harbin Medical University
                     address:
                        name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
                        type:PostalAddress
                     type:Organization
                     name:Harbin Medical University
                     address:
                        name:Department of Pharmacology (The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), Harbin Medical University, Harbin, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Role of ferroptosis in hepatocellular carcinoma
      description:Hepatocellular carcinoma (HCC) is a complicated disease with low survival rate due to frequent recurrence and the lack of efficient therapies. For advanced HCC, sorafenib, as the only approved first-line drug for HCC, improves the survival to some extent, but depressingly with severe adverse effects and emerging resistance conditions, which cause a poor prognosis. Ferroptosis is a new recognized way of non-apoptosis-regulated cell death, characterized by the iron-dependent accumulation of lipid hydroperoxides, showing a tremendous promising in the therapy of cancer, especially in HCC. To provide ideas for the diagnosis and treatment of HCC, we summarized the role of ferroptosis in HCC. The relevant literature from PubMed is reviewed in this article. Interestingly enough, investigators have found sorafenib can induce ferroptosis in HCC. Moreover, recent researches reported increasing pathways and mechanisms related to ferroptosis in HCC such as TP53 and Rb, and strategies to improve sorafenib resistance by targeting ferroptosis. In addition, other drugs were reported to induce ferroptosis in HCC such as erastin and showed good efficacy in vivo and in vitro. In this review, we summarize pathways and mechanisms of ferroptosis in HCC and other digestive system neoplasms such as gastric cancer, pancreatic cancer and colorectal cancer and point out the trends of ferroptosis in HCC.
      datePublished:2018-08-22T00:00:00Z
      dateModified:2018-08-22T00:00:00Z
      pageStart:2329
      pageEnd:2337
      sameAs:https://doi.org/10.1007/s00432-018-2740-3
      keywords:
         Hepatocellular carcinoma
         Ferroptosis
         Sorafenib
         Lipid metabolism
         Iron
         Therapy
         Oncology
         Cancer Research
         Internal Medicine
         Hematology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-018-2740-3/MediaObjects/432_2018_2740_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-018-2740-3/MediaObjects/432_2018_2740_Fig2_HTML.gif
      isPartOf:
         name:Journal of Cancer Research and Clinical Oncology
         issn:
            1432-1335
            0171-5216
         volumeNumber:144
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Jianhua Nie
            affiliation:
                  name:Cancer Hospital of Harbin Medical University
                  address:
                     name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Binlin Lin
            affiliation:
                  name:Cancer Hospital of Harbin Medical University
                  address:
                     name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Meng Zhou
            affiliation:
                  name:Cancer Hospital of Harbin Medical University
                  address:
                     name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Li Wu
            affiliation:
                  name:Cancer Hospital of Harbin Medical University
                  address:
                     name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tongsen Zheng
            url:http://orcid.org/0000-0002-7539-3924
            affiliation:
                  name:Cancer Hospital of Harbin Medical University
                  address:
                     name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
                     type:PostalAddress
                  type:Organization
                  name:Harbin Medical University
                  address:
                     name:Department of Pharmacology (The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), Harbin Medical University, Harbin, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Cancer Research and Clinical Oncology
      issn:
         1432-1335
         0171-5216
      volumeNumber:144
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Cancer Hospital of Harbin Medical University
      address:
         name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
         type:PostalAddress
      name:Cancer Hospital of Harbin Medical University
      address:
         name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
         type:PostalAddress
      name:Cancer Hospital of Harbin Medical University
      address:
         name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
         type:PostalAddress
      name:Cancer Hospital of Harbin Medical University
      address:
         name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
         type:PostalAddress
      name:Cancer Hospital of Harbin Medical University
      address:
         name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
         type:PostalAddress
      name:Harbin Medical University
      address:
         name:Department of Pharmacology (The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), Harbin Medical University, Harbin, People’s Republic of China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Jianhua Nie
      affiliation:
            name:Cancer Hospital of Harbin Medical University
            address:
               name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Binlin Lin
      affiliation:
            name:Cancer Hospital of Harbin Medical University
            address:
               name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Meng Zhou
      affiliation:
            name:Cancer Hospital of Harbin Medical University
            address:
               name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Li Wu
      affiliation:
            name:Cancer Hospital of Harbin Medical University
            address:
               name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Tongsen Zheng
      url:http://orcid.org/0000-0002-7539-3924
      affiliation:
            name:Cancer Hospital of Harbin Medical University
            address:
               name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
               type:PostalAddress
            type:Organization
            name:Harbin Medical University
            address:
               name:Department of Pharmacology (The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), Harbin Medical University, Harbin, People’s Republic of China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
      name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
      name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
      name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
      name:Department of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, People’s Republic of China
      name:Department of Pharmacology (The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), Harbin Medical University, Harbin, People’s Republic of China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {šŸ”—}(259)

Analytics and Tracking {šŸ“Š}

  • Google Tag Manager

Libraries {šŸ“š}

  • Clipboard.js
  • Prism.js

CDN Services {šŸ“¦}

  • Crossref

4.3s.